Novavax | NVAX - Operating Profit


Novavax reported $-134.02M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Adma Biologics USD 51.01M 8.21M Sep/2025
Agenus USD -13.31M 12.58M Mar/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioCryst Pharmaceuticals USD -2.54M 10.23M Dec/2024
Cassava Sciences USD -11.86M 2.23M Sep/2025
Geron USD -10.79M 3.1M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
MannKind USD -69.24M 28.19M Dec/2025
Merck USD 6.24B 318M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Moderna USD -857M 597M Dec/2025
Novartis USD 4.58B 879M Sep/2025
Novavax USD -134.02M 296.12M Sep/2024
Pfizer USD 4.65B 3.99B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025